FOREX.com by StoneX logo

Gold Intraday Up Trend Threatened by Vaccine Progress

On Wednesday, spot gold dropped as much as $30 from the day-high after Pfizer's vaccine results announcement and ended down 0.6% on day.

Global Author
Global Author

Share this:

Gold Intraday: Up Trend Threatened by Vaccine Progress

On Wednesday, U.S. pharmaceutical giant Pfizer and German biotech company BioNTech announced early positive data of its Covid-19 vaccine. Spot gold dropped as much as $30 from the day-high after the announcement and ended down 0.6%.


Pfizer said if the ongoing studies are successful and the vaccine receives regulatory approval, they "expect to manufacture up to 100 million doses by the end of 2020 and potentially more than 1.2 billion doses by the end of 2021".


Unlike the previous vaccine study results released by Moderna in May, scientists praised Pfizer for publishing the data and said the results support progressing to a larger clinical trial.


From an intraday technical point of view, spot gold risks breaking below a longer-term rising trend line as shown on the 1-hour chart. Another RSI bearish divergence is spotted when it marked a new high near $1,789. Unless the nearest resistance at $1,778 is surpassed, which is the 61.8% Fibonacci retracement resistance level of yesterday's decline, spot gold is likely to challenge the 1st and 2nd support at $1,759 and $1,747 respectively. Alternatively, a break above $1,778 might suggest that the next resistance at $1,789 would be tested again.

Source: TradingView, Gain Capital


On Wednesday, U.S. pharmaceutical giant Pfizer and German biotech company BioNTech announced early positive data of its Covid-19 vaccine. Spot gold dropped as much as $30 from the day-high after the announcement and ended down 0.6%.


Pfizer said if the ongoing studies are successful and the vaccine receives regulatory approval, they "expect to manufacture up to 100 million doses by the end of 2020 and potentially more than 1.2 billion doses by the end of 2021".


Unlike the previous vaccine study results released by Moderna in May, scientists praised Pfizer for publishing the data and said the results support progressing to a larger clinical trial.


From an intraday technical point of view, spot gold risks breaking below a longer-term rising trend line as shown on the 1-hour chart. Another RSI bearish divergence is spotted when it marked a new high near $1,789. Unless the nearest resistance at $1,778 is surpassed, which is the 61.8% Fibonacci retracement resistance level of yesterday's decline, spot gold is likely to challenge the 1st and 2nd support at $1,759 and $1,747 respectively. Alternatively, a break above $1,778 might suggest that the next resistance at $1,789 would be tested again.

Source: TradingView, Gain Capital


Related tags:

The complete CFD trading experience

Award-winning platforms, competitive spreads, low commissions and dedicated support.

We live and breathe the markets and are dedicated to helping traders realise their ambitions as we continue to set the industry bar.

Economic calendar

Web Trader platform

Our sophisticated web-based platform is packed with features.

Related articles

Gold forecast: Rising yields become too hot for gold, but the outlook is far from bearish

Gold and silver prices took a plunge today, with the former down 3% and the latter falling some 5% by mid European session, before bouncing off their lows. The losses come after the metals remained largely supported until last week, despite the big dollar rally and surging bond yields as we have seen in recent weeks. But it simply got too much, and the metals succumbed to pressure today.

StoneX Europe Ltd may make third party material available on this website which may contain information included but not limited to the conditions of financial markets. The material is for information purposes only and does not contain, and should not be construed as containing, investment advice and/or investment recommendation and/or an investment research and/or an offer of or solicitation for any transactions in financial instruments; any decision to enter into a specific transaction shall be made by the client following an assessment by him/her of their situation.

StoneX Europe Ltd makes no representation or warranty and assumes no liability as to the accuracy or completeness of the information provided, nor any loss arising from any investment based on a recommendation, forecast or other information supplied. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. We are not under any obligation to update any such material. Any opinion made may be personal to the author and may not reflect the opinion of StoneX Europe Ltd.

It's your world. Trade it.